Leadership Overview
CSL has 10 executives leading key functions including strategy, finance, operations, marketing, and information technology.
Driven by a promise to save lives, CSL leverages cutting-edge technologies to develop and deliver a dynamic portfolio of lifesaving medicines, vaccines, and therapies, impacting global health outcomes.
Driven by a promise to save lives, CSL leverages cutting-edge technologies to develop and deliver a dynamic portfolio of lifesaving medicines, vaccines, and therapies, impacting global health outcomes.
Leadership Roles at CSL
Gordon Naylor - Interim Chief Executive Officer & Managing Director
Gordon Naylor, the Interim Chief Executive Officer & Managing Director at CSL, directs the company's overarching strategy and global operations. Naylor guides CSL's mission to save lives through its portfolio of critical medicines, including treatments for hemophilia and immune deficiencies, alongside influenza vaccines and therapies for iron deficiency and nephrology. This leadership role involves ensuring CSL's continued innovation and market leadership in the biotechnology sector. Gordon Naylor's focus remains on executing the company's long-term vision and driving operational excellence across all business units. The executive's oversight extends to fostering strategic partnerships and ensuring the efficient deployment of resources to meet global healthcare needs. Naylor's direction is crucial for maintaining CSL's commitment to utilizing the latest technologies to advance patient care and improve health outcomes worldwide.
Ken Lim - Chief Financial Officer
Ken Lim, the Chief Financial Officer at CSL, oversees all financial operations and strategic financial planning for the global biotechnology company. Lim manages CSL's fiscal health, ensuring robust financial controls and driving profitable growth across its diverse portfolio of lifesaving medicines. This includes financial oversight for treatments in hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. Ken Lim's responsibilities encompass capital allocation, investor relations, and risk management, all critical to CSL's mission of saving lives through advanced technology. The Chief Financial Officer's strategic insights are vital for resource deployment and long-term financial sustainability. Lim ensures financial strategies align with the company's commitment to innovation and global market impact.
Jody Long - Administrative Advisor To Chief Financial Officer
Jody Long, the Administrative Advisor To Chief Financial Officer at CSL, provides critical support to the financial leadership team, ensuring operational efficiency within the finance department. Long assists in managing administrative functions that facilitate the strategic financial planning and execution for CSL's global operations. This support is vital for the oversight of CSL's diverse portfolio of lifesaving medicines, including treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. Jody Long's role contributes to the seamless functioning of financial processes that underpin CSL's commitment to saving lives through cutting-edge technology. The Administrative Advisor's contributions help maintain the integrity and effectiveness of financial operations, supporting CSL's mission and market impact.
Marcelo Di - Chief Financial Officer (Brazil)
Marcelo Di, the Chief Financial Officer (Brazil) at CSL, directs the financial strategy and operations within the Brazilian market. Di oversees fiscal management, ensuring financial compliance and driving economic performance for CSL's operations in the region. This includes managing financial aspects related to the company's portfolio of lifesaving medicines, such as treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology, as they pertain to the Brazilian market. Marcelo Di's financial acumen is crucial for supporting CSL's growth and its promise to save lives through the latest technologies in Brazil. The Chief Financial Officer (Brazil)'s responsibilities encompass financial planning, analysis, and reporting, ensuring alignment with global financial objectives and local market dynamics.
Emiliano Chiaramonte - Chief Financial Officer, LATAM (South)
Emiliano Chiaramonte, the Chief Financial Officer, LATAM (South) at CSL, leads financial strategy and operations across the southern region of Latin America. Chiaramonte manages fiscal planning, resource allocation, and financial performance to support CSL's mission of saving lives through its portfolio of critical medicines. This includes financial oversight for treatments in hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology within the LATAM (South) territory. Emiliano Chiaramonte's expertise is vital for driving financial sustainability and growth in diverse regional markets. The Chief Financial Officer, LATAM (South) ensures financial operations align with CSL's global objectives and its commitment to leveraging technology for improved patient outcomes across South America.
Molly Oates - Chief Operating Officer
Molly Oates, the Chief Operating Officer at CSL, directs the company's global operational strategies and execution. Oates ensures the efficient and effective delivery of CSL's lifesaving medicines, including those for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. This role involves optimizing manufacturing processes, supply chain management, and operational infrastructure across CSL's worldwide facilities. Molly Oates' leadership is essential for translating CSL's technological advancements into accessible treatments for patients globally. The Chief Operating Officer's focus is on driving operational excellence and ensuring seamless integration of new therapies into CSL's dynamic portfolio. Oates' strategic direction supports CSL's promise to save lives by enhancing production capabilities and global distribution networks.
Elizabeth Queiro - Head Chief Marketing Officer, Quality
Elizabeth Queiro, the Head Chief Marketing Officer, Quality at CSL, leads the strategic marketing initiatives and quality assurance for the company's product portfolio. Queiro ensures that CSL's lifesaving medicines, including treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology, meet the highest quality standards and reach target markets effectively. This position involves developing and implementing comprehensive marketing strategies that align with CSL's mission to save lives using the latest technologies. Elizabeth Queiro's oversight extends to brand management and market positioning, ensuring CSL's reputation for excellence. The Head Chief Marketing Officer, Quality plays a critical part in communicating the value and impact of CSL's therapeutic innovations to healthcare professionals and patients worldwide.
Phyllis Post - Vice President and Chief Information Officer, CSL Behring, Seqirus and Vifor I & T
Phyllis Post, the Vice President and Chief Information Officer, CSL Behring, Seqirus and Vifor I & T at CSL, directs the information technology strategy and infrastructure across key CSL divisions. Post is responsible for leveraging technology to support CSL's mission of saving lives through its portfolio of critical medicines and therapies. This includes overseeing IT operations for treatments in hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. Phyllis Post's leadership ensures robust data security, efficient digital workflows, and the implementation of innovative technological solutions that enhance research, development, and commercialization efforts. The Vice President and Chief Information Officer's role is pivotal in driving digital transformation and supporting CSL's commitment to utilizing cutting-edge technology for global health impact.
Candice Nieves - Manager Chief Marketing Officer Quality
Candice Nieves, the Manager Chief Marketing Officer Quality at CSL, supports the strategic marketing and quality assurance functions for the company's life-saving medicines. Nieves assists in ensuring that CSL's portfolio, which includes treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology, adheres to stringent quality standards and effectively reaches its intended audiences. This role contributes to the development and execution of marketing plans that align with CSL's core promise to save lives through advanced technology. Candice Nieves' efforts are focused on enhancing market presence and upholding the quality benchmarks that define CSL's therapeutic offerings. The Manager Chief Marketing Officer Quality supports initiatives aimed at communicating the benefits of CSL's innovations to healthcare providers and patients.
Hamza Shanaa - Manager Chief Marketing Officer Quality
Hamza Shanaa, the Manager Chief Marketing Officer Quality at CSL, contributes to the strategic marketing efforts and quality assurance processes for the company's life-saving medicines. Shanaa supports initiatives aimed at ensuring CSL's product portfolio, encompassing treatments for hemophilia, immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology, meets rigorous quality standards and effectively communicates its value. This role aids in executing marketing strategies that align with CSL's fundamental promise to save lives by employing advanced technologies. Hamza Shanaa's focus is on reinforcing CSL's market position and upholding the high-quality benchmarks associated with its therapeutic innovations. The Manager Chief Marketing Officer Quality assists in conveying the benefits of CSL's medical advancements to healthcare professionals and patients.
Explore Leadership Teams in Blood & Organ Banks
Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of our healthcare partners nationally. We provide innovative, value-added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts across Versiti result in improved patient outcomes, expanded access to care, and cost efficiencies for healthcare systems nationwide.
Company Leadership DM
BB
JF
CM
OneBlood, headquartered in Orlando, Florida, is a non-profit organization that specializes in blood donation for hospitals.
Company Leadership VC
GS
CN
DW
Founded in 1987 and headquartered in Edison, New Jersey, MTF Biologics is a tissue bank that offers allograft tissue transplant services, orthopedics, wound care, reconstructive surgery, and more.
Company Leadership FE
MK
BA
DA
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Company Leadership HA
MP
KL
SL
Frequently Asked Questions Regarding CSL Top Executives and Leadership Team
Unlock more people and company data
